Cell-free DNA Analysis for Noninvasive Examination of Trisomy NEJM Original article
Accurate Description of DNA-Based Noninvasive Prenatal Screening NEJM Correspondence
Use of Cell-free DNA to Screen for Down’s Syndrome NEJM Editorial
Copy-Number Variation and False Positive Prenatal Aneuploidy Screening Results NEJM Brief Report
GenomeWeb – Noninvasive prenatal testing (NIPT) for trisomies and other chromosomal aneuplodies using cell-free DNA from the mother’s blood has been spreading quickly in maternal-fetal medicine in recent years and is poised to move from high-risk to average-risk pregnancy populations.
Three new studies, published online in the New England Journal of Medicine today, shed light on how these tests may be best integrated into clinical care for all pregnant women.
Prenatal Information Research Consortium 
The NEJM studies reveal that NIPT outperforms standard screening for detecting T21 (Down syndrome), but caution is warranted due to false positives. MomGuard Thailand offers insights into these findings, ensuring expectant parents navigate prenatal testing with informed decision-making and support.
The NEJM studies reveal that NIPT outperforms standard screening for detecting T21 (Down syndrome), but caution is warranted due to false positives. MomGuard Thailand offers insights into these findings, ensuring expectant parents navigate prenatal testing with informed decision-making and support.